Dr.Reddy’s Laboratories (NYSE:RDY) is scheduled to issue its quarterly earnings data before the market opens on Friday, May 17th.
Shares of NYSE RDY opened at $41.86 on Friday. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 41.45 and a beta of 0.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.26 and a current ratio of 1.81. Dr.Reddy’s Laboratories has a 52-week low of $28.13 and a 52-week high of $42.82.
RDY has been the topic of a number of research analyst reports. TheStreet raised Dr.Reddy’s Laboratories from a “c+” rating to a “b” rating in a research report on Friday, February 1st. Zacks Investment Research upgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Tuesday, March 19th. CL King upgraded shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Citigroup downgraded shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, January 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.00.
Dr.Reddy’s Laboratories Company Profile
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Read More: What is a Tariff?
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.